Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Folks, getting current should by NO MEANS be an accomplishment. Dr. has $1M on his books that we haven’t collected. Simply collect some of your AR (if it’s real business) and pay your damn CPA/Attorney….
Very simple….
This guy can’t stay current, and boasts about closing world wide deals?? Are you kidding me lol
Thanks, only 50K so far traded.
My grass grows faster than VDRM.
Best place to Access the filings ???
I AM VERY IMPRESSED THAT THE FILINGS ARE FILED.WOW.I ALSO SEE HIGHER REVENUES FOR THE Q3 AND THE 9 MONTHS.BOLD SPOT.NOW HE IS ONLY HAVE TO FILE THE YEARLY REPORT.UNREAL.BRAVO TO OTIKO.NOW I AM BIDDING AGAIN.TO GET MY SHARES BACK.F$CK.
VIADERMA, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022
(UNAUDITED)
For the Three Months Ended For the Nine Months Ended
September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022
Revenue $ 150,203 $ 135,000 $ 450,433 $ 405,000
Terms of the licensing agreements “Just pay whenever you feel like it, no worries!”
Am I right in thinking the fees should be paid MONTHLY?
It appears Accounts Receivables has only increased while cash constant. How has he not collected the cash over a 3+ quarter span?
We have $1M in AR and he isn’t collecting it…. Give me the list of invoices and I’ll call myself. Or maybe he doesn’t want that because all of the revenue was generated by his other company and he doesn’t plan on paying us!
Not anymore mate!!! Fillings are in now… Late as usual but nothing to worry about now
About fucking time!!! This shall fly now
i am giving Dr Otiko the hall pass on the delays because now that filings have been done and the company listing is in good standing he can start throwing NEWS BOMBS out and the news will have a much bigger impact to share price!
FINALLY Q1 AMENDED AND Q2 AND 3 HAVE BEEN FILED!! NEED ANNUAL REPORT BY NEXT WEEK AND WE ARE FULLY REPORTING AND WILL HAVE THE YIELD SIGN LIFTED!!!
3/21. VDRM VWAP=$.0089 VOLUME=204k Bid 7 to 1
3/20. VDRM VWAP=$.0086 VOLUME=680k Bid nearly all
3/19. VDRM VWAP=$.0089 VOLUME=1k
3/18. VDRM VWAP=$.0082 VOLUME=431k Bid-side nearly all
3/15. VDRM VWAP=$.0085 VOLUME=337k Bid-side nearly all
3/14. VDRM VWAP=$.0081 VOLUME=1.2mm Bid-side 8x
3/13. VDRM VWAP=$.0087 VOLUME=1.7mm id-side 5x
If nothing changes within 30 days I would agree
Yep we are all fucked
Nobody wanting to sell. That tells me everyone is SUPER STUCK lol
GLTA
Pretty quiet day again for sure
They are a gift. :)
3/20. VDRM VWAP=$.0086 VOLUME=680k Bid nearly all
3/19. VDRM VWAP=$.0089 VOLUME=1k
3/18. VDRM VWAP=$.0082 VOLUME=431k Bid-side nearly all
3/15. VDRM VWAP=$.0085 VOLUME=337k Bid-side nearly all
3/14. VDRM VWAP=$.0081 VOLUME=1.2mm Bid-side 8x
3/13. VDRM VWAP=$.0087 VOLUME=1.7mm id-side 5x
Who is buying these shares, if everything is so, so bad? 575mm shares traded over the past year; about $8.7mm $Volume. NO NEW LOWS AND THERE ARE BUYERS FOR THE SELLERS! I will suggest things aren't as bad as some think! These shares @ $.0085 area are a gift! Bid most of the day for 2.4mm shares...
I do not think the SEC will be wasting their time looking at small time punk company, being ran like a grocery store, like Viad... Trust me, rest assured, the SEC is not onto Doctor O.
I agree: Nothing
I wish that was some kind of consolation
Things are known! Some one somewhere somehow!!!
No reason.
Just asking since someone suggested that someone knew something.
So was wondering because normally when it’s something good that someone might know, the volume would be going through the roof… and because we are about a week away from seeing the Grace Period notice from OTC for non-compliance, was just wondering…
Is the SEC looking into the company???
Did someone file a complaint?
No one selling means also, no one buying. Could be plenty of folks trying to sell, just no buyers
Oh boy... You are a good guy. I love how positive you are. Just do not consume, stay away from drugs.
Beacuse no one selling , ER on Monday or following Monday, will love to hear about new product in Poole line.
Beacuse no one selling , ER on Monday
3/19. VDRM VWAP=$.0089 VOLUME=1k
3/18. VDRM VWAP=$.0082 VOLUME=431k Bid-side nearly all
3/15. VDRM VWAP=$.0085 VOLUME=337k Bid-side nearly all
3/14. VDRM VWAP=$.0081 VOLUME=1.2mm Bid-side 8x
3/13. VDRM VWAP=$.0087 VOLUME=1.7mm id-side 5x
He will need to open a new mental facility then, The VDRM's healed group. He will drive insane the shareholders from the waiting.
Not even chess players are that patient
Busy with Wound Pros.....
Where is the Doc sinking his big head at now? The sad part is that he does not even try to dilute the stock like the rest of the Scumbags CEO the OTCM has, either. It is like he is busy with a new toy and VDRM is just, a thing of yesterday. Now he did dump it into a dark, wet and solitary room..
3/18. VDRM VWAP=$.0082 VOLUME=431k Bid-side nearly all
3/15. VDRM VWAP=$.0085 VOLUME=337k Bid-side nearly all
3/14. VDRM VWAP=$.0081 VOLUME=1.2mm Bid-side 8x
3/13. VDRM VWAP=$.0087 VOLUME=1.7mm id-side 5x
It isn’t but it can become one, depending how weak minded the Host is. LMFAO…
Fdc4 isn't that some kind of social disease. LOL
I’ll start nibbling when it hits the 75s
Ouch, wash your filthy mouth kid. What are you doing responding to a bold ass statement from someone with nothing to do? Aren’t you another idiot as well? Welcome to fan club, fanboy…
What a dumb ass statement, just another idiot with nothing to do!
I bet his bold head is shiner than ever now. Nupelo leaves it like that.. Not hair growth but it leaves the heck out of your crane, suave!!! LMAOOOO
Sunshine how is the nupelo working 4 U ?
Needed larger bulding 2 supply my 2 bottlles😄
People, Otiko got kicked out of the old location or is it a facility upgrade?
.🚨 $VDRM
— OTC Updates (@OtcUpdates) March 16, 2024
💰0.0086
Pink Limited, AS: 1.2B, OS: 1.2B, US: 1.1B
Update Delay: 72 hours
Address Updated:
🔴 4640 Admiralty Way, Ste 500, Marina Del Rey, CA, 90292, United States
🟢 5901 W Century Blvd., Ste 750, Los Angeles, CA, 90045,
https://t.co/WXYHM87e1U
Followers
|
619
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
74600
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |